Annamycin

About Moleculin Biotech

Moleculin Biotech is a micro-cap, publicly traded biopharmaceutical company advancing a late-stage pipeline anchored by Annamycin, a novel anthracycline poised to enter a pivotal Phase 3 trial (MIRACLE) for second-line AML. The company's strategy focuses on overcoming limitations of existing chemotherapies, particularly multidrug resistance and cardiotoxicity, in oncology and virology. With a valuation of approximately $10 million and a stock price near its 52-week low, the company is in a critical, capital-intensive development phase, presenting high risk but also significant potential upside if its lead program succeeds.

Therapeutic Areas